يعرض 1 - 10 نتائج من 189 نتيجة بحث عن '"Cell Surface::Receptors"', وقت الاستعلام: 0.82s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Solé C, Royo M, Sandoval S, Cortés-Hernández J Grup de Recerca en Reumatologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat de Lupus, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Moliné T, Gabaldón A Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: International Journal of Molecular Sciences;25(8); https://doi.org/10.3390/ijms25084226Test; info:eu-repo/grantAgreement/ES/PE2013-2016/PI18%2F01917; Solé C, Royo M, Sandoval S, Moliné T, Gabaldón A, Cortés-Hernández J. Precise Targeting of Autoantigen-Specific B Cells in Lupus Nephritis with Chimeric Autoantibody Receptor T Cells. Int J Mol Sci. 2024 Apr 11;25(8):4226.; https://hdl.handle.net/11351/11416Test

  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, León-Román J, Bermejo S, Bolufer M, Bestard O, Soler MJ Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CSUR National Unit of Expertise for Complex Glomerular Diseases of Spain, Barcelona, Spain. Iacoboni G Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Carpio C, Sánchez-Salinas M, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. García-Carro C Nephrology Department, San Carlos Clinical University Hospital, Madrid, Spain. Alonso-Martínez C Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Clinical Kidney Journal;17(3); https://doi.org/10.1093/ckj/sfae027Test; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI21%2F01292; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/AC22%2F00029; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/RD21%2F0005%2F0016; León-Román J, Iacoboni G, Bermejo S, Carpio C, Bolufer M, García-Carro C, et al. Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies. Clin Kidney J. 2024 Mar;17(3):27.; https://hdl.handle.net/11351/11224Test

  3. 3
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Aterido A, López-Lasanta M, Palau N, Marsal S, Julià A Grup de Recerca en Reumatologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Blanco F Rheumatology Department, Hospital Juan Canalejo, A Coruña, Spain. Juan Mas A Rheumatology Department, Hospital Son Llatzer, Palma, Spain. García Vivar ML Rheumatology Department, Hospital Universitario Barsuto, Bilbao, Spain. Erra A Grup de Recerca en Reumatologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Rheumatology Department, Hospital Sant Rafael, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Genome Biology;25; https://doi.org/10.1186/s13059-024-03210-0Test; info:eu-repo/grantAgreement/ES/PE2017-2020/PI17%2F00019; Aterido A, López-Lasanta M, Blanco F, Juan-Mas A, García-Vivar ML, Erra A, et al. Seven-chain adaptive immune receptor repertoire analysis in rheumatoid arthritis reveals novel features associated with disease and clinically relevant phenotypes. Genome Biol. 2024 Mar 11;25:68.; https://hdl.handle.net/11351/11203Test

  4. 4
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Cooper N Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, Hammersmith Hospital, London, UK. Ghanima W Department of Haemato-Oncology, Østfold Hospital Trust, Kalnes, Grålum, Norway. Department of Haematology, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Vianelli N Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Valcárcel D Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Yavaşoğlu I Department of Hematology, Adnan Menderes University, Aydın, Turkey. Melikyan A National Research Center for Hematology, Moscow, Russia, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: American Journal of Hematology;99(1); https://doi.org/10.1002/ajh.27131Test; Cooper N, Ghanima W, Vianelli N, Valcárcel D, Yavaşoğlu I, Glu Y, et al. Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial. Am J Hematol. 2024 Jan;99(1):57–67.; https://hdl.handle.net/11351/10970Test; 001114868300001

  5. 5
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Blumenberg V Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany. German Cancer Consortium (DKTK), partner site Munich, Munich, Germany. Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany. Busch G, Baumann S Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany. Jitschin R Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany. Department for Hematology and Oncology, Otto-von-Guericke University, Magdeburg, Germany. Iacoboni G, Gallur L, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Iraola-Truchuelo J Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Blood Advances;7(22); https://doi.org/10.1182/bloodadvances.2023010364Test; Blumenberg V, Busch G, Baumann S, Jitschin R, Iacoboni G, Gallur L, et al. Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL. Blood Adv. 2023 Nov 28;7(22):6844–9.; https://hdl.handle.net/11351/10816Test; 001113825800001

  6. 6
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Pérez Del Río E, Santos F, Veciana J Institute of Materials Science of Barcelona (ICMAB-CSIC), Bellaterra, Spain. Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain. Román Alonso M, Rius I Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Castellote-Borrell M Institute of Materials Science of Barcelona (ICMAB-CSIC), Bellaterra, Spain. Dynamic Biomaterials for Cancer Immunotherapy, Max Planck Partner Group (ICMAB-CSIC), Bellaterra, Spain. Arribas J Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Cytotherapy;25(12); https://doi.org/10.1016/j.jcyt.2023.08.003Test; info:eu-repo/grantAgreement/EC/H2020/754397; Pérez del Río E, Román Alonso M, Rius I, Santos F, Castellote-Borrell M, Veciana J, et al. Three-dimensional cell culture of chimeric antigen receptor T cells originated from peripheral blood mononuclear cells towards cellular therapies. Cytotherapy. 2023 Dec;25(12):1293–9.; https://hdl.handle.net/11351/10658Test

  7. 7
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Astorga-Gamaza A, Perea D, Sanchez-Gaona N, Gallego-Cortés A, Grau-Expósito J, Rey J, Curran A, Burgos J, Navarro J, Suanzes P, Falcó V, Genescà M, Buzon MJ Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Calvet-Mirabent M Universidad Autónoma de Madrid, Madrid, Spain. Immunology Unit from Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa, Madrid, Spain. Castellví J Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Cell Reports Medicine;4(10); https://doi.org/10.1016/j.xcrm.2023.101202Test; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PID2021-123321OB-I00; info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F00160; info:eu-repo/grantAgreement/ES/PE2017-2020/GLD19%2F00084; info:eu-repo/grantAgreement/ES/PE2017-2020/GLD18%2F00008; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/GLD21-00049; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/GLD22%2F00152; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/CPII22%2F00005; info:eu-repo/grantAgreement/ES/PE2013-2016/BES-2016-076382; Astorga-Gamaza A, Perea D, Sanchez-Gaona N, Calvet-Mirabent M, Gallego-Cortés A, Grau-Expósito J, et al. KLRG1 expression on natural killer cells is associated with HIV persistence, and its targeting promotes the reduction of the viral reservoir. Cell Rep Med. 2023 Oct 17;4(10):101202.; https://hdl.handle.net/11351/10552Test

  8. 8
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Solano C Department of Hematology, Institute for Research (INCLIVA), Hospital Clínico Universitario, Valencia, Spain. School of Medicine, Department of Medicine, University of Valencia, Valencia, Spain. Castro-Rebollo P Medical Intensive Care Unit, Hospital Clinic de Barcelona, Barcelona, Spain. Pérez-Martínez A Pediatric Hemato-Oncology Department, La Paz University Hospital, Madrid, Spain. López-Corral L Hematology Service, Hospital Clínico Universitario de Salamanca, Salamanca, Spain. Barba-Suñol P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Kwon M Hematology Service, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: BMJ Open;13(7); http://dx.doi.org/10.1136/bmjopen-2022-071371Test; Solano C, Castro-Rebollo P, Pérez-Martínez A, López-Corral L, Barba-Suñol P, Kwon M, et al. Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study. BMJ Open. 2023 Jul 25;13(7):e071371.; https://hdl.handle.net/11351/10150Test

  9. 9
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Rejeski K, Blumenberg V Department of Medicine III – Hematology/Oncology, University Hospital, LMU Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany. Bavarian Cancer Research Center (BZKF), Partner Sites Munich and Erlangen, Germany. Iacoboni G, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament of Medicina, Universitat Autònoma of Barcelona, Bellaterra, Spain. Lopez-Corral L Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain. Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain. Kharboutli S Bavarian Cancer Research Center (BZKF), Partner Sites Munich and Erlangen, Germany. Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Germany. Hernani R Hematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: HemaSphere;7(4); http://dx.doi.org/10.1097/HS9.0000000000000858Test; Rejeski K, Blumenberg V, Iacoboni G, Lopez-Corral L, Kharboutli S, Hernani R, et al. Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL. HemaSphere. 2023 Apr;7(4):e858.; https://hdl.handle.net/11351/9433Test

  10. 10
    دورية أكاديمية

    المساهمون: García-Corbacho J Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain. Medical Oncology Department (UGCI), Virgen de La Victoria and Regional University Hospital / IBIMA, Málaga, Spain. Indacochea A Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain. Medical Oncology Department, Hospital General de Granollers, Granollers, Spain. González Navarro AE Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain. Victoria I, Moreno D, Pesántez D Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain. Nogué M Medical Oncology Department, Hospital General de Granollers, Granollers, Spain, Hospital General de Granollers

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Cancer Immunology, Immunotherapy; https://doi.org/10.1007/s00262-022-03360-9Test; García-Corbacho J, Indacochea A, González Navarro AE, Victoria I, Moreno D, Pesántez D, et al. Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study. Cancer Immunol Immunother. 2023 Jan 10.; https://hdl.handle.net/11351/9545Test